Syfovre, the PEGylated version of a 2nd-generation compstatin-based C3 therapeutic (Cp05) discovered in my lab at the University of Pennsylvania (pubmed.ncbi.nlm.nih.gov/1685…) shows a consistent safety profile over 36 months of treatment, with increasing efficacy in reducing GA lesion size and a projected benefit in prespecified functional analyses. Read the data from the 12-month extension clinical study of Syfovre here: sciencedirect.com/science/ar… 4th generation compstatin analogs (in development by Amyndas) with more favorable properties in terms of ocular residence time, tissue distribution, target binding affinity and inhibitory potency (see our study here: pubmed.ncbi.nlm.nih.gov/3222…)  have the potential to become an even more efficacious and patient-compliant treatment for GA and other ocular inflammatory diseases. sciencedirect.com/science/ar…

Amid the dust settling from the 'explosion' of clinical approvals, here's our spotlight w/@LambrisJD on the first ever therapy for patients with geographic atrophy, the #compstatin based #C3 targeted drug #Syfovre #pegcetacoplan Now out in @TrendsinPharma sciencedirect.com/science/ar…

Happy 70th @LambrisJD!! Here holding his "brainchild" #compstatin #Cp40 right next to its target #C3, the complement protein whose evolution, structure and many functions John has pioneered for more than 40 yrs! @AegeanConf @ComplementSoc

That's fantastic news for the patients and another breakthrough for #xenoTx! I remember first discussing with Bob Montgomery @nyulangone the prospects of applying #C3 inhibition in Tx with multiple projected benefits! In fact, we had established the potential of C3 inhibition in ex vivo xenoTx models of pig #kidney and #heart perfusion with human blood, using the initially discovered compstatin and its third-generation  analog Cp40 (see:lambris.com/pdf/118-article.… and  lambris.com/pdf/608-article.…) Delighted to see that this journey of science and discovery has advanced to actual clinical studies in living recipients with the pioneering work of Bob Montgomery and his team and the inclusion of the C3 therapeutic Empaveli as part of the immunosuppressive regimen to prevent organ rejection. Empaveli is based on the second-generation #compstatin derivative Cp05 discovered by my team at Penn Medicine (see lambris.com/pdf/37-article.p…). That said, the future for C3 therapeutics in xenotransplantation looks bright indeed!

Back in 2016 we first posited that C3 inhibition would afford therapeutic benefit in C3G ncbi.nlm.nih.gov/pmc/article… Compstatin Cp40/AMY-101 could restore complement regulation in C3G models. Happy to see that pegcetacoplan now shows efficacy in Phase II: pubmed.ncbi.nlm.nih.gov/3802…

Glad to see the two Phase III studies of #Syfovre in #GA patients completed and published! Witnessing the evolution of #Compstatin analog Cp05, discovered in my lab @Penn back in 2006, all the way from bench to bedside has been such a gratifying experience thelancet.com/journals/lance…

Elated to see our 2nd gen compstatin-based C3 inhibitor find its way to patients with GA, an inflammatory ocular disease with such a huge burden! Remarkable news and a great thrust to continue improving compstatins! investors.apellis.com/news-r…

Scientists from @UniBasel_en, @PennMedicine, @UniLeipzig and @UniUtrecht provide molecular insights into the mode-of-action of the compstatin family of complement inhibitors. #compstatins, #therapeutics @RicklinLab, @LambrisJD and @ChristinaLamers go.nature.com/3sMfjjP

The second article is "Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research – 20 years of experience and future perspectives" by Tom Mollnes, Benjamin S. Storm, Ole L. Brekke, Per H. Nilsson & @LambrisJD sciencedirect.com/science/ar…

Here's a new study supporting therapeutic C3 modulation in AMD. Pegcetacoplan, based on 2nd generation compstatin Cp05 discovered in my lab, slows GA progression and is associated with reduced photoreceptor degeneration nature.com/articles/s41598-0…

Peculiarities of Complement C3 inhibition explained @NatureComms doi.org/10.1038/s41467-022-3… #complement #compstatin #complement #CompChem #DrugDesign

Happy to see our study published in @NatureComms on the fascinating cyclic peptide #compstatin Cp40 and its molecular determinants to high affinity. Such a great collaborative work with Daniel Ricklin, @LambrisJD and Piet Gros labs. #research #macrocycles #peptides #WomenInSTEM

Excited to share the latest chapter in the #compstatin saga now out in @NatureComms Great collaboration with Daniel Ricklin’s & Piet Gros’ groups! Insight into mode-of-action and structural determinants of the compstatin family! nature.com/articles/s41467-0…

Great honour for our group to contribute in this innovative work! Time to try compstatin against systemic thromboinflammation in complement-mediated diseases beyond COVID-19

Delighted to see our work finally out in @ScienceAdvances!New mechanistic and biological insights into systemic C3 inhibition with #compstatin #AMY101 in severe #COVID19 Clinical effort led by @PSkendros, Ritis & an international team of collaborators! science.org/doi/10.1126/scia…

From our special issue on #C3 therapeutics: #Compstatin-based inhibitors are poised to revolutionize C3-targeted #therapy for #AMD #GA & other #ocular diseases! To get a grasp on the latest developments in this rapidly evolving field check out our review: sciencedirect.com/science/ar…

Happy to share article #2 of our special issue w/ @dmastellos on #C3 #therapeutics! Mechanistic-clinical insights and prospects of C3-targeted host modulation with #compstatin-based #AMY101 in #periodontal & #peri_implant inflammatory diseases #oralhealth authors.elsevier.com/a/1fDQ~…

Discusses the findings of the study by @RSchmitz21 et al in a highly sensitized primate model of kidney Tx where compstatin analog Cp40 mitigated early AMR and prolonged graft survival: nature.com/articles/s41467-0…

CLINICAL HIGHLIGHT Mastellos et al describes the history of C3-inhibitors and the final approval of pegcetacoplan for the treatment for paroxysmal nocturnal hemoglobinuria (PNH). A must-read article about the fascinating story of compstatin! Check it out⬇️ pubmed.ncbi.nlm.nih.gov/3414…

The approval of #pegcetacoplan, a 2nd gen compstatin-based C3 inhibitor in 2021 serves as critical validation of C3-targeted treatment. This review traces the #evolution of compstatins from their academic 'roots' to the clinic and highlights current and future clinical directions